DUBLIN--(BUSINESS WIRE)--The 'Growth Opportunities in Biologics Contract Development and Manufacturing Organizations, 2024-2029' report has been added to ResearchAndMarkets.com's offering.

都柏林--（商业新闻短讯）--“2024-2029年生物制品合同开发和制造组织的增长机会”报告已添加到ResearchAndMarkets.com的产品中。

This analysis provides detailed revenue forecasts for the global market of bio-CDMOs. The forecasts are categorized by market and segment, offering valuable insights into the industry. The analysis focuses on highlighting the potential growth opportunities for participants by considering trends, business models, and innovative strategies..

该分析为全球生物CDMOs市场提供了详细的收入预测。这些预测按市场和细分市场进行分类，为行业提供了有价值的见解。该分析侧重于通过考虑趋势、商业模式和创新战略，突出参与者的潜在增长机会。。

By 2023, biologics constituted 44% of the therapeutic pipeline, with antibodies and recombinant proteins as leading categories. Nevertheless, advancements in these fields decelerated, with most of the expansion happening in heterologous cell treatments, synthetic nucleic acids, and viruses. The global biologics pipeline will shift toward more complex treatment modalities, including cell and gene therapy (CGT), nucleic acid therapy, ADC, and bispecific antibodies..

到2023年，生物制剂占治疗管道的44%，抗体和重组蛋白为主要类别。然而，这些领域的进步减缓了，大部分扩展发生在异源细胞治疗，合成核酸和病毒中。全球生物制剂管道将转向更复杂的治疗方式，包括细胞和基因治疗（CGT），核酸治疗，ADC和双特异性抗体。。

Biopharmaceutical companies that focus on these treatments will strive for reduced durations for clinical development and a greater focus on cost-effectively producing drugs with lower costs of goods sold (COGS). Biologics contract development and manufacturing organizations (Bio-CDMOs) are actively framing manufacturing and supply chain strategies, with a specific emphasis on partnering with service providers to optimize the production process..

专注于这些治疗的生物制药公司将努力缩短临床开发的持续时间，并更加关注以较低的销售成本（COGS）生产具有成本效益的药物。生物制品合同开发和制造组织（Bio-CDMO）正在积极制定制造和供应链战略，特别强调与服务提供商合作以优化生产过程。。

The US Inflation Reduction Act (IRA) and the BIOSECURE Act have the potential to slow down drug innovation and the demand for CDMO services, leading to radical transformations in global outsourcing dynamics and CDMO strategies. Venture capitalists are assisting their pharmaceutical portfolios by internally restructuring and extending their cash reserves..

。风险资本家正在通过内部重组和扩大现金储备来协助其制药投资组合。。

CDMOs have experienced a consistent decrease in demand, especially for the initial phases of development. However, in late 2023 and 2024, there was a rise in M&A transactions, favorable conditions for biotech financing and valuation, and a stabilization of inflation and interest rates. Demand will resurge, particularly from emerging biopharma and early-stage development, by 2024..

CDMO的需求持续下降，尤其是在开发的初始阶段。然而，在2023年末和2024年，并购交易有所增加，生物技术融资和估值的有利条件以及通货膨胀和利率的稳定。到2024年，需求将复苏，特别是新兴生物制药和早期开发。。

The market segments cover various aspects, such as product type, cell expression type, modality, and geographic region. Considering the end of the COVID-19 pandemic and the current global geopolitical issues, demand for outsourcing has decelerated. CDMOs are experiencing a decline in demand, particularly from small and emerging biopharmaceutical companies and those in the early stages of development..

市场细分涵盖各个方面，例如产品类型，细胞表达类型，形态和地理区域。考虑到新型冠状病毒疫情的结束和当前的全球地缘政治问题，外包需求已经放缓。CDMO的需求正在下降，特别是来自小型和新兴生物制药公司以及处于开发早期阶段的公司。。

This analysis provides a comprehensive examination of future trends, covering the period between 2024 and 2029. It includes insights on capacity expansions, mergers, acquisitions, and the expansion of service offerings. The analysis also investigates the impact of strategic imperatives, growth drivers, restraints, revenue share estimates, and opportunities for bio-CDMOs..

该分析全面审查了2024年至2029年期间的未来趋势。它包括对容量扩展、合并、收购和服务产品扩展的见解。该分析还调查了战略需求、增长驱动因素、限制因素、收入份额估计以及生物CDMO机会的影响。。

Growth Opportunity Universe in Bio-CDMO

生物CDMO中的增长机会宇宙

Expanding Drug Product Capabilites to Support Anti-obesity Drugs

扩大药品能力以支持抗肥胖药物

Providing End-to-end mRNA Services

提供端到端mRNA服务

Indian Domestic Players Enhance Biologics Capabilities

印度国内企业增强生物制剂能力

Key Topics Covered:

涵盖的关键主题：

Growth Environment - Transformation in the Bio-CDMO Sector

增长环境-生物CDMO行业的转型

Why is it Increasingly Difficult to Grow?

为什么增长越来越困难？

The Strategic Imperative

The Impact of the Top 3 Strategic Imperatives on the Bio-CDMO Industry

前三大战略要务对生物CDMO行业的影响

Growth Environment - Ecosystem in Bio-CDMO

生物CDMO中的生长环境-生态系统

Biologics Industry - Outlook

生物制品行业-展望

Biologics Industry - Key Therapeutic Area Outlook

生物制品行业-关键治疗领域展望

Biologics Pipeline by Modality and Phase

按形态和阶段划分的生物制剂管道

Biologics Industry - Market size and Growth Rate Forecast by Modality

生物制品行业-市场规模和增长率预测（按形态）

Global Trends Impacting the Bio-CDMO Industry

影响生物CDMO行业的全球趋势

Industry Trends Impacting the Bio-CDMO Industry

影响生物CDMO行业的行业趋势

Business Model - Shift from Fee-for-service to Value-based Risk-sharing

商业模式-从按服务收费转向基于价值的风险分担

Value-based Risk-sharing Business Model

基于价值的风险分担商业模式

Scope of Analysis

分析范围

Segmentation

细分

Segmentation

细分

Competitive Environment

竞争环境

Key Competitors

主要竞争对手

Growth Generator

生长发生器

Growth Metrics

增长指标

Growth Drivers

增长驱动因素

Growth Restraints

增长限制

Forecast Considerations

预测注意事项

Forecast Framework - Bio-CDMO Market Sizing

预测框架-生物CDMO市场规模

Forecast Methodology - Bio-CDMO Market

预测方法-生物CDMO市场

Revenue Forecast

收入预测

Revenue Forecast by Product Type

按产品类型划分的收入预测

Revenue Forecast by Cell-culture Type

按细胞培养类型划分的收入预测

Revenue Forecast by Region

按地区划分的收入预测

Revenue Forecast by Modality

按方式划分的收入预测

Revenue Forecast Analysis

收入预测分析

Revenue Forecast Analysis by Region

按地区划分的收入预测分析

Revenue Share

收入份额

Revenue Share Analysis

收入份额分析

Cell and Gene Therapy

细胞和基因治疗

Growth Metrics

增长指标

Revenue Forecast

收入预测

Forecast Analysis

预测分析

Vaccines

疫苗

Growth Metrics

增长指标

Revenue Forecast

收入预测

Forecast Analysis

预测分析

Antibody Therapeutics

抗体治疗学

Growth Metrics

增长指标

Revenue Forecast

收入预测

Forecast Analysis

预测分析

Proteins and Peptides

蛋白质和肽

Growth Metrics

增长指标

Revenue Forecast

收入预测

Forecast Analysis

预测分析

Best Practice Recognition in Bio-CDMO

生物CDMO最佳实践认可

For more information about this report visit https://www.researchandmarkets.com/r/rd1y4e

有关此报告的更多信息，请访问https://www.researchandmarkets.com/r/rd1y4e

About ResearchAndMarkets.com

关于ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ResearchAndMarkets.com是全球领先的国际市场研究报告和市场数据来源。我们为您提供有关国际和地区市场、关键行业、顶尖公司、新产品和最新趋势的最新数据。